Growth delay in Down syndrome and zinc sulphate supplementation.
Children affected with Down syndrome (DS) show deficient growth, immunodeficiency--especially concerning the T-cell population--and low plasma zinc levels. New growth charts have been recently proposed, and zinc supplementation to the diet has been reported to improve transiently the efficiency of the immune system. The aim of this study was to evaluate if in DS children zinc sulphate therapy could improve the growth rate and affect some endocrine parameters. We studied 22 patients (16 males and 6 females) who received zinc sulphate for 6 to 9 months. Fifteen of 22 patients studied reached a higher centile in their growth rate, whereas the remaining seven showed no change, at least to date. The average height velocity changed from 23.84 +/- 7.98 mm/6 months to 40.80 +/- 7.68 mm/6 months. Growth hormone serum level was 5.94 +/- 4.89 ng/ml compared with 7.49 +/- 6.75 ng/ml before and after therapy, respectively. Somatomedin serum level was 160.27 +/- 68.88 mU/ml and 205 +/- 124.07 mU/ml before and after therapy, respectively. In conclusion, zinc sulphate therapy of patients with DS affects not only the immune system, as previously reported, but can also accelerate growth.
Napolitano
G
G
Chair of Endocrinology, University G. D'Annunzio, Chieti, Italy.
Palka
G
G
Grimaldi
S
S
Giuliani
C
C
Laglia
G
G
Calabrese
G
G
Satta
M A
MA
Neri
G
G
Monaco
F
F
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004314:Down Syndrome / Q000150:complications / Q000503:physiopathology*; D005260:Female; D006130:Growth Disorders / Q000150:complications* / Q000188:drug therapy; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D008297:Male; D013002:Somatomedins / Q000378:metabolism; D013431:Sulfates / Q000627:therapeutic use*; D015032:Zinc / Q000627:therapeutic use*; D019287:Zinc Sulfate
D013002:Somatomedins; D013431:Sulfates; D019287:Zinc Sulfate; D013006:Growth Hormone; D015032:Zinc